Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 10/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 9/20 | 0.40 |
| ▸ | DUT | P33316 | 1/20 | 0.39 |
| ▸ | POLG | P54098 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13614916 | 0.86 | POLB (0.52) | P2RY2POLBP2RY6P2RY4 | |
| SCHEMBL16325834 | 0.86 | POLB (0.52) | P2RY2POLBP2RY6P2RY4 | |
| SCHEMBL14017374 | 0.79 | RNASE1 (0.35) | P2RY2POLBP2RY6P2RY4DUT | |
| SCHEMBL14400570 | 0.79 | RNASE1 (0.35) | P2RY2POLBP2RY6P2RY4DUT | |
| SCHEMBL13614535 | 0.76 | POLB (0.60) | P2RY2POLBP2RY6P2RY4DUT | |
| SCHEMBL14017366 | 0.76 | POLB (0.60) | P2RY2POLBP2RY6P2RY4DUT | |
| SCHEMBL13614531 | 0.73 | POLB (0.64) | P2RY2POLBP2RY6P2RY4 | |
| SCHEMBL13629375 | 0.73 | POLB (0.64) | P2RY2POLBP2RY6P2RY4 | |
| SCHEMBL13614925 | 0.71 | P2RY6 (0.54) | P2RY2POLBP2RY6P2RY4DUT | |
| SCHEMBL13614567 | 0.71 | P2RY6 (0.54) | P2RY2POLBP2RY6P2RY4DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612047-B2 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612047-B2 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090076256-A1 | DEGRADATION-RESISTANT MONONUCLEOSIDE PHOSPHATE COMPOUNDS | DOUGLASS III JAMES G | 2009-03-19 | — | — | US | disclosed |
| US-20090076256-A1 | DEGRADATION-RESISTANT MONONUCLEOSIDE PHOSPHATE COMPOUNDS | DOUGLASS III JAMES G | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076256-A1 | DEGRADATION-RESISTANT MONONUCLEOSIDE PHOSPHATE COMPOUNDS | PNKP, ENTPD5, ENPP1 | P2RY2 75/4885POLB 160/4885P2RY6 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.